Natera, Inc. (NASDAQ:NTRA):
Natera fÃ¼r Langschnittstudie zu zirkulierender Tumor-DNA in Brustkrebs ausgewÃ¤hlt.
The company is so far trading up from yesterday’s close of $10.99.
Natera, Inc., launched on January 26, 2007, is a diagnostics company. The Company is involved in the discovery, development and commercialization of genetic testing services. The Company operates a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) providing a host of preconception and prenatal genetic testing services..
Shares last traded at $10.99 significantly below $12.76, the stock’s 50 day moving average and which is significantly lower than the 200 day moving average of $12.78. The 50 day moving average went down by -13.90% and the 200 day average went down by -14.01%.
As of the latest earnings report the EPS was $-2.43 and is estimated to be $-2.08 for the current year with 53,223,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.39 with next year’s EPS anticipated to be $-1.13.
Traders are feeling more bullish on shares of Natera, Inc. recently if you watch the fall in short interest. The company recorded a fall in short interest of -4.97% as of the latest report on October 13, 2017. Short shares fell from 1,364,345 to 1,296,515 over that period. Days to cover decreased -1.0 to 8.0 and the short interest percentage is 0.02% as of October 13.
A few brokerage analysts have provided guidance on the company recently. August 7 investment analysts at Morgan Stanley maintained a company rating of “Overweight” but lowered the price target to $13.00 from $20.00. On October 6 Morgan Stanley made no change to the company rating of “Overweight” but raised the price expectation from $13.00 to $16.00.